Review of Checkpoint Inhibitor Immunotherapy in Neuroendocrine Tumor of Prostate and Our Experience in 2 Cases

Neuroendocrine prostate cancer (NEPC) is a rare entity. De novo NEPC is extremely rare; other cases are usually adenocarcinoma previously treated with hormonal therapies transforming to NEPC. Most of the cases are metastatic at diagnosis and regardless of the histology types, the prognosis is poor....

Descripción completa

Detalles Bibliográficos
Autores principales: Pokhrel, Akriti, Nair, Kiron, Jaswani, Vijay, Salyana, Muhammad, Mooppan, Unni, Wang, Jen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052808/
https://www.ncbi.nlm.nih.gov/pubmed/35473437
http://dx.doi.org/10.1177/23247096221093886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052808/
https://www.ncbi.nlm.nih.gov/pubmed/35473437
http://dx.doi.org/10.1177/23247096221093886

Ejemplares similares